Skip to Main Content

News & Views

Press Releases

Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline

Financing led by founding investors Polaris Partners and ARCH Venture Partners alongside Lilly. Funding will...

Volastra Therapeutics Named One of Fierce Biotech’s “Fierce 15” Companies of 2022

September 12, 2022

NEW YORK, September 12, 2022 – Volastra Therapeutics, an oncology company focused on exploiting chromosomal...

Volastra Therapeutics to Present Preclinical Data from KIF18A Inhibitor Program Targeting Chromosomally Unstable Tumors at FASEB Aneuploidy Conference

September 9, 2022

Treatment with KIF18A inhibitor led to substantial, dose-dependent inhibition of tumor growth in multiple tumor...

In The News

Lilly-Backed Volastra Enters Clinic with Amgen’s KIF18A Inhibitor

Volastra licenses Amgen molecule for chromosomally unstable cancers

Armed with $60M series A and Lilly’s backing, Volastra enters clinic via Amgen cancer med